DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Related studies linked through entity extraction aliases.